SLC-3010
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for SLC-3010, covering 2026-03-13 to 2026-03-13. Get the full timeline:
Most recent: Clinical Trial Update: An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma [Phase 2]